Vernalis PLC: Notice of Interim Results Period Ended 31 Dec 2014

WINNERSH, UNITED KINGDOM--(Marketwired - Jan 30, 2015) - Vernalis PLC (LSE: VER) (OTC PINK: VNLPY)

30 January 2015
LSE: VER

Notice of Interim Results for the Periods Ended 31 December 2014

Vernalis plc today announces its unaudited interim results for the six month and twelve month periods ended 31 December 2014 will be released on Tuesday, 10 February 2015. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com.

Further to the announcement of 18 November 2014, and pursuant to the change to the Company's accounting reference date from 31 December to 30 June, the Company's audited results for the 18 month period to 30 June 2015 will be announced by the end of September 2015.

Following the results announcement, the Company will host an analyst presentation and concurrent conference call at 9:00 am (UK) on 10 February 2015. The presentation will be held at the offices of Brunswick Group, 16 Lincoln's Inn Fields, London, WC2A 3ED. Please contact Valerie Mugridge at Brunswick on +44 (0) 207 396 5325 for details.

-- ends --

Enquiries:

Vernalis plc:
Ian Garland, Chief Executive Officer	+44 (0) 118 938 0015
David Mackney, Chief Financial Officer
Canaccord Genuity Limited (Nominated Adviser):	+44 (0) 20 7523 8350
Lucy Tilley
Dr Julian Feneley
Henry Fitzgerald-O'Connor
Shore Capital (Joint Broker):	+44 (0)20 7408 4090
Bidhi Bhoma
Toby Gibbs
Brunswick Group:	+44 (0) 20 7404 5959
Jon Coles

Notes to Editors

About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.